Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework-Reference-Cited by-同舟云学术

Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework

Published:2020-02 Issue: Volume:246 Page:112595
ISSN:0277-9536
Container-title:Social Science & Medicine
language:en
Short-container-title:Social Science & Medicine

Author:

Angelis A.^ORCID,Linch M.,Montibeller G.^ORCID,Molina-Lopez T.,Zawada A.,Orzel K.,Arickx F.,Espin J.,Kanavos P.

Funder

European Commission

Publisher

Elsevier BV

Subject

History and Philosophy of Science,Health(social science)

Reference115 articles.

1. Informe de Posicionamiento Terapéutico Pt-Enzalutamida/V1/30072015;AEMPS,2015

2. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American college of cardiology/American heart association task force on performance measures and task force on practice guidelines;Anderson;J. Am. Coll. Cardiol.,2014

3. Evaluating the benefits of new drugs in health technology assessment using multiple criteria decision analysis: a case study on metastatic prostate cancer with the dental and pharmaceuticals benefits agency (TLV) in Sweden;Angelis;MDM Pol. Pract.,2018

4. Critique of the American society of clinical oncology value assessment framework for cancer treatments: putting methodologic robustness first;Angelis;J. Clin. Oncol.,2016

5. Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment;Angelis;PharmacoEconomics,2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolving value assessment of cancer therapies: Results from a modified Delphi study;Health Policy OPEN;2024-12

2. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review;Frontiers in Pharmacology;2024-04-24

3. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration;Current Oncology;2024-04-01

4. Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: A qualitative institutional case study;PLOS ONE;2024-03-18

5. Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review;International Journal of Health Policy and Management;2024-02-10